Sarepta Therapeutics Inc (NASDAQ:SRPT) Receives Consensus Recommendation of “Buy” from Analysts
Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) have received an average recommendation of “Buy” from the twenty-one ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, nineteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $206.82.
SRPT has been the topic of a number of research analyst reports. HC Wainwright set a $267.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 17th. Morgan Stanley dropped their target price on shares of Virtus Investment Partners from $121.00 to $118.00 and set an “equal weight” rating on the stock in a research note on Tuesday, July 9th. Cowen restated a “buy” rating and issued a $77.00 target price on shares of Centene in a research note on Sunday, March 31st. Royal Bank of Canada downgraded shares of Roku from an “outperform” rating to a “sector perform” rating and set a $90.00 target price on the stock. in a research note on Monday, July 1st. They noted that the move was a valuation call. Finally, Piper Jaffray Companies restated a “hold” rating on shares of Seattle Genetics in a research note on Thursday, March 28th.
In other news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,200,000.00. Following the transaction, the director now directly owns 21,717 shares in the company, valued at $2,606,040. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.60% of the stock is currently owned by company insiders.
Sarepta Therapeutics stock traded down $2.37 during midday trading on Friday, reaching $149.26. The stock had a trading volume of 946,860 shares, compared to its average volume of 1,237,047. The company has a debt-to-equity ratio of 0.35, a quick ratio of 11.15 and a current ratio of 12.17. Sarepta Therapeutics has a 52-week low of $95.21 and a 52-week high of $165.87. The company has a market capitalization of $11.06 billion, a price-to-earnings ratio of -27.34 and a beta of 2.12. The stock has a fifty day simple moving average of $136.32.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.05) by $0.98. The company had revenue of $87.01 million for the quarter, compared to analyst estimates of $86.92 million. Sarepta Therapeutics had a negative net margin of 124.66% and a negative return on equity of 36.26%. On average, equities analysts forecast that Sarepta Therapeutics will post -4.04 EPS for the current fiscal year.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Recommended Story: How Do You Make Money With Penny Stocks?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.